Carter Gould
Stock Analyst at Barclays
(3.39)
# 920
Out of 4,784 analysts
197
Total ratings
49.15%
Success rate
2.06%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $165 | $113.16 | +45.81% | 12 | Dec 23, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $95 | $111.79 | -15.02% | 14 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,080 → $1,065 | $637.36 | +67.10% | 19 | Nov 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $19.68 | +1.63% | 6 | Nov 1, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,025 → $975 | $822.51 | +18.54% | 11 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $138.37 | +30.09% | 24 | Oct 31, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $42 → $43 | $60.02 | -28.36% | 14 | Oct 7, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $142 → $140 | $89.23 | +56.90% | 10 | Oct 7, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $315 | $306.95 | +2.62% | 16 | Oct 7, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $212 | $205.29 | +3.27% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $73.05 | +36.89% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.75 | +298.46% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $32 | $25.21 | +26.93% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.05 | +185.71% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.65 | +445.45% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $43.19 | +119.96% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $19.66 | +1.73% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $67.96 | +7.42% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.23 | +334.59% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.29 | +830.23% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.17 | +28.21% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.52 | +335.79% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $218.75 | +73.71% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $60.60 | +35.31% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $492.69 | -61.84% | 1 | Jul 26, 2018 |
Neurocrine Biosciences
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $113.16
Upside: +45.81%
Gilead Sciences
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $84 → $95
Current: $111.79
Upside: -15.02%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,080 → $1,065
Current: $637.36
Upside: +67.10%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $19.68
Upside: +1.63%
Eli Lilly and Company
Oct 31, 2024
Maintains: Overweight
Price Target: $1,025 → $975
Current: $822.51
Upside: +18.54%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $138.37
Upside: +30.09%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Underweight
Price Target: $42 → $43
Current: $60.02
Upside: -28.36%
Merck & Co.
Oct 7, 2024
Maintains: Overweight
Price Target: $142 → $140
Current: $89.23
Upside: +56.90%
Amgen
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $306.95
Upside: +2.62%
AbbVie
Oct 7, 2024
Maintains: Overweight
Price Target: $200 → $212
Current: $205.29
Upside: +3.27%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $73.05
Upside: +36.89%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.75
Upside: +298.46%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $30 → $32
Current: $25.21
Upside: +26.93%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.05
Upside: +185.71%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.65
Upside: +445.45%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $43.19
Upside: +119.96%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $19.66
Upside: +1.73%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $67.96
Upside: +7.42%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.23
Upside: +334.59%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.29
Upside: +830.23%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.17
Upside: +28.21%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.52
Upside: +335.79%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $218.75
Upside: +73.71%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $60.60
Upside: +35.31%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $492.69
Upside: -61.84%